Thus, specific blockade of the immune checkpoints cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or programmed cell death protein 1 (PD-1) has shown potential in the treatment of different types of cancer by promoting T cell responses in patients. This evidence concerns the gene CTLA4 and cancer.